Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, shared new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The company presented data demonstrating that its next-generation suppressor tRNAs (sup-tRNAs) restore full‑length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Tevard also presented data showing that its novel sup-tRNAs provide durable rescue of full-length titin protein in a mouse model as well as functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM‑TTNtv).
The findings underscore the potential of Tevard's suppressor tRNA platform to address a broad range of genetic diseases caused by premature termination codons. The company's next‑generation sup-tRNAs achieved approximately 100% restoration of full‑length dystrophin in DMD models, a significant improvement over earlier approaches. Additionally, the titin rescue data indicate that the therapy can produce durable, full-length protein in models of TTN-related cardiomyopathy, which currently has limited treatment options.
Tevard's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. The presented programs highlight the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner. For more information, visit www.tevard.com.
About Tevard Biosciences: Tevard Biosciences is pioneering tRNA‑based and other mRNA‑modulating therapies to cure a broad range of genetic diseases. The company’s suppressor tRNA platform is designed to restore endogenous, full‑length protein expression for diseases caused by premature termination codons. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders.
